Medivir AB (publ)
Research Medivir AB (publ) (MVR0) on Bullrun: market cap EUR 73.51M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMVR0
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 73.51M
- Financial periodQ1 2026
- RevenueSEK 1.00M
- Net income-SEK 9.40M
- Free cash flow-SEK 13.00M
Valuation Snapshot
latest market cap is EUR 73.51M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 8.50M | -SEK 94.40M | -SEK 73.40M | n/a | -0.64 | SEK 31.95M | SEK 8.39M | SEK 155.21M |
| FY2024 | n/a | -SEK 123.32M | -SEK 124.19M | n/a | -1.08 | SEK 62.53M | SEK 11.07M | SEK 115.52M |
| FY2023 | n/a | -SEK 89.32M | -SEK 59.67M | n/a | -1.48 | SEK 169.52M | n/a | SEK 217.93M |
| FY2022 | n/a | -SEK 88.77M | -SEK 102.20M | n/a | -1.59 | SEK 117.43M | n/a | SEK 192.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 73.51M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Medivir AB (publ)
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medivir AB (publ)'s market cap?
Medivir AB (publ)'s market capitalization is EUR 73.51M.
What does Medivir AB (publ) do?
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C.